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a  b  s  t  r  a  c  t
Social  isolation  stress  (SIS)  paradigm  is  a  chronic  stress  procedure  able  to  induce  profound  behavioral
and  neurochemical  changes  in rodents  and evokes  depressive  and anxiety-like  behaviors.  Recent  studies
demonstrated  that  the  cannabinoid  system  plays  a key  role  in  behavioral  abnormalities  such  as  depres-
sion  through  different  pathways;  however,  there  is no  evidence  showing  a relation  between  SIS  and  the
cannabinoid  system.  This  study  investigated  the role  of  the cannabinoid  system  in  depressive-like  behav-
ior  and  anxiety-like  behavior  of  IC animals.  For  this  purpose,  NMRI  mice  were  treated  with  WIN55,  212-2
(non-selective  cannabinoid  receptor  agonist)  and  AM-251  (cannabinoid  receptor  type 1 antagonist)  and
AM-630  (cannabinoid  receptor  type 2 antagonist).  We  found  that  behavioral  abnormality  followed  by  SIS
was  mitigated  after  administration  of  WIN55,  212-2.  Also,  depressive-like  effects  induced  by  SIS were  sig-ouse niﬁcantly  increased  following  administration  of AM-251  and  AM-630.  Co-administration  of  cannabinoid
receptor  antagonists  (AM-251  and  AM-630),  signiﬁcantly  reversed  the antidepressant  effect  of  WIN55,
212-2  in  IC animals.  Our  ﬁndings  suggest  that the  cannabinoid  system  is involved  in  depressive-like
behaviors  induced  by  SIS.  We  showed  that  activation  of  cannabinoid  receptors  (type  1 and  2) could
mitigate  depression-like  behavior  induced  by SIS  in  a  mouse  model.
©  2017  Elsevier  Inc.  All  rights  reserved.. Introduction
Evidences from clinical and pre-clinical studies have demon-
trated that early life exposure to environmental and social
tressors plays a pivotal role in the development of psychi-
tric disorders such as depression (Lupien et al., 2009; Pechtel
nd Pizzagalli, 2011). In this regards, it has been shown that
ocial isolation stress (SIS) paradigm is a chronic stress pro-
edure able to induce profound behavioral and neurochemical
hanges in rodents and evokes depressive and anxiety-like behav-
ors (Fone and Porkess, 2008; Weiss et al., 2004; Nestler and Hyman,
∗ Corresponding author at: Experimental Medicine Research Center, Tehran Uni-
ersity of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.
E-mail addresses: dehpour@yahoo.com, dehpoura@sina.tums.ac.ir (A.R. Deh-
our).
1 Please note that the ﬁrst two authors are considered as the ﬁrst authors.
ttp://dx.doi.org/10.1016/j.brainresbull.2017.01.018
361-9230/© 2017 Elsevier Inc. All rights reserved.2010; Koob et al., 1989). Glutaminergic system, nitrergic system,
hypothalamic-pituitary-adrenal (HPA) axis are pathways known to
mediate the impacts of SIS on psychopathologies like depression
(Weiss et al., 2004; Haj-Mirzaian et al., 2015; Amiri et al., 2014).
The cannabinoid system comprises the cannabinoid receptors
(CB1 and CB2 receptors) and represents an important neuromod-
ulator in the central nervous system (CNS) (Devane et al., 1992;
Dinh et al., 2004; Gong et al., 2006; Matsuda et al., 1990; Sugiura
et al., 1995). Recent studies demonstrated that the cannabinoid sys-
tem exerts its antidepressant effects through different pathways
including the modulation of HPA axis function (Weidenfeld et al.,
1994), regulating the release of neurotransmitters (Domenici et al.,
2006; Takahashi and Castillo, 2006) and the modulation of neuro-
inﬂammation (Walter and Stella, 2004).Although, antithesis evidence has shown different effects for
cannabinoids on behavior, overall, effects of cannabinoids depend
on the doses and time of administration as well as experimental
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onditions (Rodriguez Bambico et al., 2009; Witkin et al., 2005);
owever, the exact mechanisms modulated by the cannabinoid sys-
em are still unknown. Therefore, further investigations are needed
o clarify the mechanisms underlying the antidepressant-like
ffects of these pharmacological agents targeting the cannabinoid
ystem. Previous reports have determined that cannabinoid recep-
or (CBR) agonists can reverse the depressive state in animals
xposed to chronic mild stress; however, there is no evidence
howing that cannabinoid agonists have beneﬁcial effects in
epression following SIS paradigm (Segev et al., 2014).
Considering the above-mentioned points, we tried to demon-
trate the impact of the cannabinoid system on depressive-like
ehaviors induced by SIS. The aim of our study is to investigate the
ffects of drugs acting on CB1 and CB2 receptors (CB1R and CB2R)
n depressive-like behavior in SIS mice using WIN55,212-2 (non-
peciﬁc agonist) and AM630 (CB2R antagonist) and AM251 (CB1R
ntagonist). For this purpose, we used SIS paradigm as a chronic
tress model. Behavioral experiments to measure depressive-like
ehavior including forced swimming test (FST), splash test and
pen ﬁeld-test (OFT) were used in order to verify our hypothesis.
. Materials and methods
.1. Animals and housing conditions
Male NMRI mice (Pasteur Institute, Tehran, Iran) weighing
0–12 g on postnatal day (PND) 21–24 were used in this study (ani-
als used in this study were at adolescence period) (Spinelli et al.,
013). Animals were housed under standard laboratory conditions
s temperature at 22 ± 2C, humidity at 50, 12-h light–dark cycle,
nd free access to food and water ad-lib for a period of 28 days in
wo opposing conditions: social condition (SC) or isolated condition
IC). Socially conditioned mice were located (6 per cage) in Plexiglas
oxes (25 cm × 25 cm × 15 cm)  and IC animals were placed individ-
ally in Plexiglas boxes (24 cm × 17 cm × 12 cm)  (Amiri et al., 2015).
he cages of IC animals were cleaned weekly by a same experi-
enter to diminish handling and social interaction. All experiments
ere conducted during the period between 10:00 a.m. and 02:00
.m. Each mouse was used only once in each tests. Each experi-
ental group contained 6–8 animals. All experiments were carried
ut in accordance with National Institutes of Health (NIH) Guide for
he Care and Use of Laboratory Animals (NIH publication #80-23)
nd institutional guidelines for animal care and use (Department
f Pharmacology, School of medicine, Tehran University of Medical
ciences).
.2. Drugs
AM-251 (CB1R antagonist), AM-630 (CB2R antagonist) and
IN55, 212-2 (non-selective agonist of CBR) were purchased from
igma (Sigma, St Louis, MO,  USA). AM-251 and AM-630 were dis-
olved in saline and WIN55, 212-2 dissolved in dimethyl sulfoxide
DMSO) and further diluted with 5% Tween-80 and 90% saline (0.9%
aCl). Final DMSO concentration was 5%. Injections were carried
ut through intraperitoneal (i.p.) route in a constant volume of
 ml/kg body weight. DMSO, Tween-80 and saline solutions were
sed as vehicle (Vehicle: 1:1:18 of DMSO, Tween-80 and saline,
espectively).
AM-251 (0.2 and 0.5 mg/kg) and AM-630 (0.2 and 0.5 mg/kg)
ere administrated 30 min  before behavioral tests (Kruk-Slomka
t al., 2015; Ostadhadi et al., 2016) and WIN55, 212-2 (1, 3 and
 mg/kg) was administered 60 min  prior to the behavioral tests
Bambico et al., 2007). Doses and time of administrations of each
rug were chosen based on our pilot study and pervious published Bulletin 130 (2017) 200–210 201
reports (Haj-Mirzaian et al., 2016a; Haj-Mirzaian et al., 2016c;
Weiss et al., 2004).
2.3. Experiment design and treatments
In the ﬁrst part of study, the effects of SIS on depressive-like
behaviors were investigated using previously validated behavioral
tests including forced swimming test (FST), open-ﬁeld test (OFT)
and splash test. On the next step, the possible effects of CBR ago-
nist/antagonists on IC mice were assessed. To do this, mice (IC and
SC) were treated with the sub-effective doses of AM-630 (0.2 and
0.5 mg/kg, i.p., 30 min  prior to the tests), AM-251 (0.2 and 0.5 mg/kg,
i.p., 30 min  prior to the tests) and WIN55, 212-2 (1, 3 mg/kg and
5 mg/kg, i.p., 60 min  prior to the tests). After administration of
drugs, behaviors of animals were evaluated using aforementioned
behavioral tests. To exclude the possible impact of saline and vehi-
cle administrations, mice were treated with 5 ml/kg physiological
saline as well as vehicle before carrying out behavioral tests.
2.4. Open-ﬁeld test (OFT)
Just before the FST, the locomotor activity of animals was  eval-
uated using the open-ﬁeld test (Haj-Mirzaian et al., 2016a; Kaster
et al., 2005; Haj-Mirzaian et al., 2016b), in order to rule out the
possibility that changes in duration of immobility are not the
result of modiﬁcations in motor activity. OFT was used to eluci-
date the locomotor activity in response to SIS (Walsh and Cummins,
1976). The apparatus of OFT was  made of white opaque Plexiglas
(50 cm × 50 cm × 30 cm)  and was  faintly illuminated. Each animal
was placed gently on the central zone (30 cm × 30 cm)  and behav-
iors were recorded using a camera for a 5 min  period and were
analyzed by Ethovision software version 8 (Noldus, Netherlands).
The surface of the apparatus was cleaned with 70% ethanol after
each experiment. Each animal was used in only one experiment.
The distance moved and the numbers of rearings were evaluated.
2.5. Forced swimming test (FST)
FST was carried out by using the method of Porsolt et al. (Porsolt
et al., 1977a; Porsolt et al., 1977b; Haj-Mirzaian et al., 2016c). Mice
were separately placed in an open cylinder-shaped ﬂask (diame-
ter 10 cm,  height 25 cm), containing 19 cm water at 23 ± 1 ◦C. Mice
were allowed to swim for 6 min  and the period of immobility was
recorded throughout the last 4 min  of the test. Each mouse was
considered immobile when it ceased struggling and stayed ﬂoating
motionless in the water, making only those movements necessary
to keep its head above water.
2.6. Splash test
This test was used to evaluate self-care and motivational behav-
iors. In this test, grooming activity time of mice, which can be
considered as an indirect measure of palatable solution intake, was
measured. A 10% sucrose solution was squirted on the dorsal coat
of animals in their home cage and mice were videotaped for 5 min.
The total grooming activity time was recorded for 5 min  after the
sucrose vaporization (Detanico et al., 2009). Grooming activity con-
sists of nose/face grooming, head washing and body grooming.
2.7. Statistical analysisComparisons between the groups were assessed using t-test and
one-way ANOVA followed by Tukey’s post hoc test using GraphPad
Prism 6 software (San Diego, CA, USA). P values less than 0.05 were
considered statistically signiﬁcant.
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ean  ± S.E.M. from 6 to 8 animals and were analyzed using t-test. **P < 0.01 and ***
. Result
.1. Effect of social isolation stress on depressive- like behaviors
Results obtained from the t-test analysis showed that SIS
nduced depressive-like behaviors in FST and splash test. SIS signif-
cantly increased the immobility time in the FST (t = 4.967, df = 12,
 < 0.001, Fig. 1A) and signiﬁcantly decreased the grooming activ-
ty time in splash test (t = 9.890, df = 13, P < 0.001, Fig. 1B) when
ompared to SC control animals. In the open-ﬁeld test, IC animals
howed higher locomotor activity, including total distance moved
t = 3.442, df = 14, P < 0.01, Fig. 1C) and number of rearings (t = 4.467,
f = 14, P < 0.001, Fig. 1D) in comparison with SC mice.
.2. Effect of WIN55, 212-2 on depressive-like behaviors
Administration of WIN55, 212-2 (a non-selective CB1R/CB2R
gonist) reversed depressant-like effect of SIS in IC animals, while
ad no effects on SC mice.
One-way ANOVA analysis showed that administration of
IN55, 212-2 signiﬁcantly decreased immobility time in the FST
F (3, 24) = 1.193, P < 0.001, Fig. 2B) and increased grooming activ-
ty time in the splash test (F (3, 24) = 0.2696, P < 0.001, Fig. 2D) of
C mice when compared to saline-treated IC mice. Tukey’s analy-
is showed that WIN55, 212-2 at doses of 3 and 5 mg/kg i.p. has
igniﬁcant effects on FST (P < 0.001) and splash test (P < 0.01). Also,
dministration of WIN55, 212-2 at 1 mg/kg/i.p. showed no effect
n FST (P > 0.05) and splash test (P > 0.05) of IC animals. In addition,
here was no signiﬁcant effect between non-treated IC and vehicle-
reated IC (P > 0.05). Administration of aforementioned drug at any
ose had no signiﬁcant effects on IC mice in both distance moved
F (3, 28) = 0.3453, P > 0.05, Fig. 2F) and number of rearings (F (3,
8) = 0.4109, P > 0.05, Fig. 2H) as measured in the OFT.Post- test analysis showed that administration of WIN55, 212-2
t higher dose (5 mg/kg) exerted a signiﬁcant effect on immobil-
ty time of the FST (F (3, 24) = 1.526, P > 0.05 Fig. 2A) in SC animals.
ne-way ANOVA analysis showed that injection of WIN55, 212-2sh test (B) and locomotor activity in the OFT (C and D). Values are expressed as
001 IC (isolated condition) and SC (social condition) animals were compared.
had no signiﬁcant effect on the grooming activity time in the splash
test (F (3, 28) = 1.600, P > 0.05 Fig. 2C), locomotor activity (F (3,
28) = 0.4010, P > 0.05 Fig. 2E) and vertical activity (F (3, 28) = 0.8368,
P > 0.05 Fig. 2G) of the OFT in SC-treated animals when compared to
the saline-treated SC group. Tukey’s analysis revealed that admin-
istration of WIN55, 212-2 at 5 mg/kg/i.p. signiﬁcantly decreased
immobility time in SC animals when compare with saline-treated
animals (P < 0.05); however, no signiﬁcant effect was seen after
administration of 1 and 3 mg/kg in the FST (P > 0.05). Also, adminis-
tration of WIN55, 212-2 at doses of 3 and 5 mg/kg/i.p. had not any
effects on FST (P > 0.05), splash test (P > 0.05) and OFT (P > 0.05) in SC
animals when compare to saline-treated animals. Results obtained
by comparing the non-treated IC and vehicle-treated IC animals
showed no signiﬁcant differences between these groups (P > 0.05).
3.3. Blockade of CB1R and CB2R increases depressive-like
behavior
One-way ANOVA analysis revealed that administration of AM-
251 in IC mice increased immobility time in the FST in comparison
with saline-treated IC mice (F (2, 18) = 0.6922, P < 0.01, Fig. 3B). Also,
AM-251 decreased grooming activity time in the splash test (F (2,
18) = 3.522, P < 0.05, Fig. 3D). On the other hand, locomotor activ-
ity (F (2, 21) = 0.3344, P > 0.05 Fig. 2F) and vertical activity (F (2,
21) = 2.392, P > 0.05 Fig. 3H) were not changed in the OFT after
administration of AM251. Tukey’s analysis showed that admin-
istration of AM251 at 0.5 mg/kg i.p. showed signiﬁcant effect on
FST (P < 0.01) and splash test (P < 0.05) of IC animals when com-
pared with saline-treated IC mice. However, administration of
lower dose of AM-251 (0.2 mg/kg/i.p.) in IC animals did not alter
the immobility, grooming times, distance moved and the number
of rearings in comparison to saline-treated IC group (P > 0.05). Also,
results revealed no signiﬁcant differences between non-treated and
vehicle-treated IC animals (P > 0.05).
After injection of AM-251 in SC mice, one-way ANOVA analy-
sis demonstrated no differences between drug-treated SC animals
and saline-treated SC animals in FST (F (2, 18) = 0.3537, P > 0.05,
A. Haj-Mirzaian et al. / Brain Research Bulletin 130 (2017) 200–210 203
Fig. 2. Effects of WIN55, 212-2 (1, 3 and 5 mg/kg) on IC mice (B, D, F and H) and SC mice (A, C, E and G); despair behavior in the FST (A and B), self-care behavior in the
splash  test (C and D), distance moved in the OFT (E and F) and number of rearings in the OFT (G and H). Values are expressed as mean ± S.E.M. from 6 to 8 animals and were
analyzed using one-way ANOVA followed by Tukey’s post hoc test. *P < 0.05, **P < 0.01 and ***P < 0.001, drug-treated mice from each group were compared with corresponding
vehicle-treated animals.
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Fig. 3. Effects of AM-251 (0.2 and 0.5 mg/kg) on IC group (B, D, F and H) and SC group (A, C, E and G); despair behavior in the FST (A and B), self-care behavior in the splash
test  (C and D), distance moved in the OFT (E and F) and number of rearings in the OFT (G and H). Values are expressed as mean ± S.E.M. from 6 to 8 animals and were analyzed
using  one-way ANOVA followed by Tukey’s post hoc test. *P < 0.05 and **P < 0.01, drug-treated mice from each group were compared with corresponding vehicle-treated
animals.
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Fig. 4. Effects of AM-630 (0.2 and 0.5 mg/kg) on IC group (B, D, F and H) and SC group (A, C, E and G); despair behavior in the FST (A and B), self-care behavior in the splash
test  (C and D), distance moved in the OFT (E and F) and number of rearings in the OFT (G and H). Values are expressed as mean ± S.E.M. from 6 to 8 animals and were analyzed
using  one-way ANOVA followed by Tukey’s post hoc test. *P < 0.05 and **P  < 0.01, drug-treated mice from each group were compared with corresponding vehicle-treated
animals.
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Fig. 5. Effects of co-administration of AM-251 (0.5 mg/kg) and WIN55, 212-2 (5 mg/kg) on behavioral despair in the FST (A), self-care behavior in the splash test (B), distance
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ig. 3A), splash test (F (2, 21) = 0.9670, P > 0.05, Fig. 3C) and OFT
distance moved (F (2, 21) = 1.463, P > 0.05, Fig. 3E)) and number of
earings (F (2, 21) = 0.1039, P > 0.05, Fig. 3G). In addition, no signiﬁ-
ant effect was found between non-treated and vehicle-treated SC
nimals (P > 0.05).
One-way ANOVA revealed that AM-630 exerted signiﬁcant
ffects on depressive-like behaviors of IC mice in the FST (F (2,
8) = 0.2816, P < 0.01, Fig. 4B) and splash test (F (2, 18) = 1.604,
 < 0.05, Fig. 4D). Also, data showed that AM-630 injection had
ot signiﬁcant effects in both locomotor activity (F (2, 21) = 1.525,
 > 0.05, Fig. 4F) and vertical activity (F (2, 21) = 0.2135, P > 0.05,
ig. 4H) of OFT in IC animals.
Tukey’s analysis revealed that injection of AM-630 signiﬁcantly
ncreased immobility time in FST at the highest dose (0.5 mg/kg)
P < 0.01) and decreases grooming activity in splash test when used
t 0.2 mg/kg (P < 0.05) and 0.5 mg/kg (P < 0.01); however, AM-630
ailed to show any signiﬁcant effects in the OFT (P > 0.05). Also,
o signiﬁcant difference was found between no non-treated and
ehicle-treated IC animals (P > 0.05).
However, the results were different in SC mice. Administration
f AM-630 to SC mice showed antidepressant-like effect in the FST
F (2, 18) = 1.525, P < 0.05, Fig. 4A) and splash test (F (2, 21) = 4.929, < 0.05, Fig. 4C). On the other hand, no signiﬁcant difference was
een after injection of AM-630 in distance moved (F (2, 21) = 0.8115,pressed as mean ± S.E.M. from 6 to 8 animals and were analyzed using one-way
 WIN55, 212-2-treated group. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with
P > 0.05, Fig. 4E) and number of rearnigs (F (2, 21) = 1.708, P > 0.05,
Fig. 4G) in OFT.
Tukey’s analysis showed that administration of AM-630 sig-
niﬁcantly decreased immobility time in FST at the highest dose
(0.5 mg/kg) (P < 0.01) and increased grooming activity in splash test
when used at 0.2 mg/kg (P < 0.05) and 0.5 mg/kg (P < 0.01); however,
AM-630 failed to show any signiﬁcant effects in the OFT  (P > 0.05).
3.4. CBR1 and CBR2 receptor antagonists reverse the effects of
CBR agonist in SIS
To further investigate the role of the cannabinoid system on
depressive-like behaviors following SIS, we  carried out simulta-
neous administration of WIN55, 212-2 (60 min  before tests) with
AM-251 (30 min  before tests) or AM-630 (30 min  before test).
Results from abovementioned experiment showed that both
AM-251 and AM-630 reversed the effects of WIN55, 212-2. One-
way ANOVA analysis showed that co-administration of AM-251
increased immobility time in the FST (F (3, 24) = 0.9986, P < 0.001,
Fig. 5A) and decreased grooming activity time in the splash test (F
(3, 24) = 0.8833, P < 0.001, Fig. 5B) when compared to WIN55,212-
2-treated IC mice. On the other hand, no effect was detected in the
distance moved of OFT results in IC (F (3, 28) = 0.06603, P > 0.05,
Fig. 5C) after administration of AM-251 plus WIN55,212-2. Also,
we did not detect any signiﬁcant effect in the number of rearings
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ollowed by Tukey’s post hoc test. ###P < 0.001 and $$P < 0.01 compared with the WIN
F (3, 28) = 0.4705, P > 0.05, Fig. 5D) in the OFT after co-
dministration of the two drugs. Result from Tukey’s study showed
hat administration of both AM-251 and WIN55, 212-2 reversed
he effects of WIN55, 212-2 in both FST (P < 0.001) and splash test
P < 0.01) in IC mice.
One-way ANOVA showed that AM-630 reversed the effects of
IN55,212-2 in the FST (F (3, 24) = 0.4947, P < 0.001, Fig. 6A) and
plash test (F (3, 24) = 0.7111, P < 0.001, Fig. 6B) in IC mice. Fig. 6C
hows that AM-630 and WIN55, 212-22 co-injection had no signif-
cant effects on distance moved of OFT (F (3, 24) = 0.2586, P > 0.05,
ig. 6C) and number of rearings (F (3, 28) = 0.1826, P > 0.05, Fig. 6D)
n IC mice. Result obtained from Tukey’s revealed that AM-630 co-
njection reversed the effects of WIN55, 212-2 on the FST (P < 0.001)
nd splash test (P < 0.01) in IC mice.
.5. Co-administration of CBR agonist with CBR antagonists in SC
nimals
To further clarify the involvement of the cannabinoid system in
he pathophysiology of depression induced by SIS, we investigated
he effect of co-administration of the CBR antagonists with CBR
gonist in SC animals. In this regard, we injected WIN55, 212-22
60 min  before tests) prior to administration of AM-251 and AM-
30 (30 min  before tests) in SC mice.
One-way ANOVA analysis showed no signiﬁcant difference
etween WIN55, 212-22-treated animals and co-administration of
M-251 with WIN55, 212-22 in the FST (F (3, 24) = 0.9888, P > 0.05,
ig. 7A), the splash test (F (3, 28) = 1.088, P > 0.05, Fig. 7B), distance
oved of the OFT (F (3, 28) = 0.6489, P > 0.05, Fig. 7C) and number
f rearings (F (3, 28) = 0.2688, P > 0.05, Fig. 7D) in SC mice. behavioral despair in the FST (A), self-care behavior in the splash test (B), distance
sed as mean ± S.E.M. from 6 to 8 animals and were analyzed using one-way ANOVA
2-2-treated group. **P < 0.01 and ***P < 0.001 compared with vehicle-treated group.
On the other hand, one-way ANOVA analysis revealed that injec-
tion of AM-630 plus WIN55, 212-22 in SC animals does not induce
any signiﬁcant effect as compared to WIN55, 212-22-treated mice
in FST (F (3, 24) = 0.1773, P < 0.01, Fig. 8A), distance moved of the
OFT (F (3, 28) = 0.6352, P > 0.05, Fig. 8C) and number of rearings (F
(3, 28) = 1.587, P > 0.05, Fig. 8D). However, one-way ANOVA showed
that there is a signiﬁcant difference between co-injection (AM-630
with WIN55, 212-22) and AM-630-treated animals in the splash
test (F (3, 28) = 3.915, P < 0.001, Fig. 8B). Results obtained from
Tukey’s analysis revealed that grooming activity time after injec-
tion of AM-630 and WIN  was  signiﬁcantly longer as compared with
animals treated with WIN  alone in the splash test (P < 0.001).
4. Discussion
The results described in the present study showed that
the depressive-like behaviors induced by SIS are mitigated
through the activation of CBRs. Our results provided evidence for
antidepressant-like effects of WIN55, 212-22 (CB1R and CB2R non-
selective agonist) on IC mice using a number of previously validated
behavioral tests, which are valid in rodents. In addition, we showed
that antidepressant-like effects of WIN55, 212-22 were prevented
by co-administration of CB1R antagonist (AM-251) or CB2R antag-
onist (AM-630). We  found that administration of WIN55, 212-22
in IC mice signiﬁcantly decreased immobility time in the FST, and
increased grooming activity time in the splash test. Furthermore,
antidepressant-like effects of WIN55, 212-22 reversed following
co-administration with AM-630 (CB2R antagonist) and AM251
(CB1R antagonist).
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SIS in early life is known as a pivotal risk factor for the develop-
ent of psychiatric disorders such as depression (Fone and Porkess,
008; Weiss et al., 2004; Grippo et al., 2008). Previous studies
ave demonstrated that SIS provoked anxiety and depressive-like
ehaviors in animal models (Grippo et al., 2008). In the current
tudy, using FST (increase in the immobility time) and splash test
decrease in grooming activity time) we showed that SIS induced
epressive-like behaviors in IC animals in comparison to SC mice.
ncrease in immobility time in the FST reﬂects the depressive mood
despair behavior) in rodents (Cryan et al., 2005). Additionally, we
sed splash test in order to investigate self-care behavior. Decrease
n grooming activity in the splash test reﬂects self-care difﬁcul-
ies in rodents (Detanico et al., 2009; Willner, 2005). Our ﬁndings
howed that IC mice showed an increase in immobility time in the
ST as well as a decrease in grooming activity time in the splash
est. We  used OFT to evaluate the effects of SIS and treatments on
otor function, exploratory behavior, and to exclude possible alter-
tions in locomotion that might affect FST (Kulesskaya and Voikar,
014; Amiri et al., 2016). OFT was performed directly before the
ST to assess ambulatory behavior and also to prove that variations
hich occur in motor activity did not affect the immobility time
Kaster et al., 2005).
The cannabinoid system is a neuromodulator system which clas-
ically consists of the CB1R and CB2R (Matsuda et al., 1990; Gerard
t al., 1991). The cannabinoid system is involved in many physi-
logical processes such as appetite, pain-sensation, memory and
ood (Rodriguez Bambico et al., 2009; Cota et al., 2003; Marsicano
t al., 2002). Previous studies have shown that stress, fear and
motions alter the expression of the CB1R in different regions of
he brain such as amygdala, nucleus accumbens (NAc), hippocam- behavioral despair in the FST (A), self-care behavior in the splash test (B), distance
sed as mean ± S.E.M. from 6 to 8 animals and were analyzed using one-way ANOVA
pus, and pre-frontal cortex (PFC) (Breivogel and Sim-Selley, 2009;
Herkenham et al., 1991; Pazos et al., 2005).
Evidence indicates that both CBR antagonists and agonists are
able to produce antidepressant-like effects in different animal mod-
els of depression (Rodriguez Bambico et al., 2009). In this regard
it should be noted that there is an inconsistency in the literature
regarding the effect of CBR activation and/or inhibition on depres-
sion state.
In this regard, there are some studies reporting that CBR agonists
decrease immobility in the FST without affecting locomotor activity
in the OFT in a rat model (Hill and Gorzalka, 2005; Jiang et al., 2005).
In addition, other studies showed that CBR antagonists exerted
antidepressant-like effect by decreasing the immobility time with-
out any change in locomotor activity in a mouse model (Takahashi
et al., 2008; Tzavara et al., 2003). These results may be related to
some fundamental differences between the rat and mice cannabi-
noid system. Overall, it could be concluded that both cannabinoid
agonists and antagonists have antidepressant-like effect.
A study by Macri and Laviola has shown that the effects of
WIN55, 212-2 on depressive-like behaviors induced by early-life
stress are dose dependent in a mouse model. Indeed, administra-
tion of WIN55, 212-2 at low dose (0.5 mg/kg, intraperitoneal once
daily for 3 days) has antidepressant-like effect and there is no sig-
niﬁcant effect at high dose (2 mg/kg, intraperitoneal once daily for
3 days) (Macrııa`nd Laviola, 2004). However, these data differ from
the reported antidepressant- like activity of acute high doses of
the CB1R antagonist Rimonabant (Tzavara et al., 2003; Shearman
et al., 2003) or the inverse agonist AM-251 (Shearman et al., 2003)
in mice. Our results showed that administration of WIN55, 212-2
at doses of 3 and 5 mg/kg i.p. signiﬁcantly reversed depressive-
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oved  in the OFT (C) and number of rearings in the OFT (D) in SC group. Values are e
ollowed by Tukey’s post hoc test. $$P < 0.01 compared with the WIN55, 212-2-treat
ike behaviors provoked by SIS as measured in the FST and splash
est while dose 1 mg/kg i.p. had no signiﬁcant effect in these tests.
urthermore, WIN55, 212-2 at aforementioned doses had no sig-
iﬁcant effect in the OFT. The reason of inconsistency between the
esults of our work with previously mentioned studies may  be asso-
iated with the different animal models used (social isolation and
aternal separation) and also the duration of drug administration
acute and chronic WIN55, 212-2 injection).
Data from previous studies showed that CB2R agonists have
ntidepressant-like effect in a rat model (Hu et al., 2009). In
ine with previously mentioned studies, our ﬁndings showed
hat WIN55, 212-2 (a non-selective agonist of CBR) elicited
ntidepressant-like activity in IC mice. Administration of the CB2R
ntagonist, similarly to the CB1R antagonist, signiﬁcantly reversed
he antidepressant properties of WIN.
In this study, we showed that CBR agonist (WIN55, 212-22) has
ntidepressant-like effect at doses of 3 mg/kg and 5 mg/kg in SC
ice. This suggests that both CBRs are involved in the pathway of
epression-like behavior induced by SIS in mice.
Although literature has shown that CBRs play a role in depres-
ion, little is known about the relation between SIS and the
annabinoid system (Zamberletti et al., 2012; Sciolino et al.,
010). In this study, we investigated to investigate the role of
he cannabinoid system in a mouse model of SIS. Data from our
tudy showed the possible role for the involvement of cannabi-
oid system in depressive-like behaviors induced by SIS. This study
howed that CB1R and CB2R agonist reversed the depressive-
ike behaviors of SIS whereas co-administration of CB1R or CB2R
elective antagonists with CBR non-selective agonist reversed the behavioral despair in the FST (A), self-care behavior in the splash test (B), distance
sed as mean ± S.E.M. from 6 to 8 animals and were analyzed using one-way ANOVA
up. *P < 0.05 and **P < 0.01 compared with vehicle-treated group.
antidepressive-like effect of CBR agonist (increase in immobility
time as well as decrease in grooming activity time).
5. Conclusion
Our results showed that the CBRs are involved in depressive-like
behaviors induced by SIS. In this study, we  showed that CB1R and
CB2R are both involved in promoting antidepressant-like effects in
the SIS mouse model.
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